Onyx @ Jefferies: Lubor Gaal, CFO, Circio

Circular RNA is edging toward a modality breakout - and Circio is one of the few players with early pharma validation.

circVec has shown up to 40× higher protein expression and ~75× longer RNA stability in vivo, tackling gene therapy’s core bottleneck: durable expression without vector overload.